All In Biotech

Drug Trial Radar · NCT00884221

MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer

A Randomized, Open-label, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy of MENOPUR Versus Recombinant FSH in Controlled Ovarian Stimulation Following a GnRH Antagonist Protocol and Single Embryo Transfer

Last checked: Nov 20, 2026Latest source record: Apr 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 749 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

749

Actual

Start

Jul 2009

Primary completion

Jul 2010

Study completion Jan 2011

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 21 years, up to 34 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this clinical research trial was to compare the ongoing pregnancy rate between two gonadotrophins for controlled ovarian stimulation (MENOPUR and recombinant follicle-stimulating hormone (FSH)), in cycles where a gonadotrophin-releasing hormone (GnRH) antagonist was used for prevention of premature luteinizing hormone (LH) surge and where a single embryo was transferred at the blastocyst stage.

Conditions

  • Infertility

Interventions

  • Highly purified menotrophinDrug

    The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days. NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.

  • Recombinant FSHDrug

    The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days. NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis SetTime frame: 10-11 weeks after embryo transfer at the blastocyst stage
  2. Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Per-protocol (PP) Analysis SetTime frame: 10-11 weeks after embryo transfer at the blastocyst stage

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • ERASME Hospital

    Anderlecht, Belgium

  • UZ Brussel

    Brussels, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Gent

    Ghent, Belgium

  • IVF Institute

    Pilsen, Czechia

  • ISCARE IVF a.s.

    Prague, Czechia

  • Pronatal

    Prague, Czechia

  • H:S Rigshospitalet

    Copenhagen, Denmark

  • Amtssygehuset Herlev

    Herlev, Denmark

  • Sygehus Vestsjælland

    Holbæk, Denmark

  • H:S Hvidovre Hospital

    Hvidovre, Denmark

  • KRIOBANK

    Bialystok, Poland

  • nOvum

    Warsaw, Poland

  • IU Dexeus

    Barcelona, Spain

  • GINEFIV, Madrid

    Madrid, Spain

  • IVI Madrid

    Madrid, Spain

  • Ginemed

    Seville, Spain

  • IVI Sevilla

    Seville, Spain

  • IVI Valencia

    Valencia, Spain

  • Fertilitetscentrum AB Gothenburg

    Gothenburg, Sweden

  • IVF-kliniken CURA

    Malmö, Sweden

  • RMC, Malmö

    Malmö, Sweden

  • Hacettepe University

    Ankara, Turkey (Türkiye)

  • American Hospital

    Istanbul, Turkey (Türkiye)

  • Memorial Hospital

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.